{"product_id":"glioblastoma-immunotherapy-and-the-aging-immune-system-what-older-patients-need-to-know","title":"Glioblastoma Immunotherapy and the Aging Immune System: What Older Patients Need to Know","description":"\u003cp\u003eThis systematic review and meta-analysis examined 30 clinical trials involving 556 glioblastoma (GBM) patients to determine whether older age affects how well immunotherapy works. Researchers found that patients aged 65 and older had a significantly higher risk of dying within one year of immunotherapy treatment compared to younger patients (risk ratio 1.29, p=0.004), with the effect even stronger in newly diagnosed GBM (risk ratio 2.34, p=0.0026). The study also uncovered a troubling pattern: GBM clinical trials disproportionately enroll younger patients, with only 18% of participants aged 65 or older, despite GBM being primarily a disease of older adults (median age at diagnosis: 64). This age bias was not present in lung cancer immunotherapy trials, suggesting GBM trials may not accurately represent the patient population most affected by this disease.\u003c\/p\u003e\n\n\u003ch1\u003eGlioblastoma Immunotherapy and the Aging Immune System: What Older Patients Need to Know\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#aging-immune\"\u003eThe Aging Immune System Explained\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eStudy Methods: How the Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#findings-overall\"\u003eKey Finding #1: Higher Risk of Death in Older Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#findings-newly\"\u003eKey Finding #2: Age Matters More in Newly Diagnosed GBM\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#findings-vaccine\"\u003eKey Finding #3: Vaccine-Based Therapies May Be More Affected by Age\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#findings-bias\"\u003eKey Finding #4: Clinical Trials Are Skewed Toward Younger Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations: What This Research Couldn't Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients and Researchers\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eA meta-analysis of 30 trials (556 patients) found older GBM patients had a 29% higher risk of death within one year of immunotherapy.\u003c\/li\u003e\n\u003cli\u003eIn newly diagnosed GBM, patients 65+ had more than double the risk of dying within one year (risk ratio 2.34).\u003c\/li\u003e\n\u003cli\u003eVaccine-based immunotherapies showed a 38% increased risk for older patients, but the difference was not clearly stronger than non-vaccine therapies.\u003c\/li\u003e\n\u003cli\u003eOnly 18% of phase II and 26% of phase III GBM immunotherapy trial participants were aged 65+, skewing results toward younger patients.\u003c\/li\u003e\n\u003cli\u003eLung cancer immunotherapy trials had a balanced age split, but GBM trials enrolled younger patients, raising concerns about real-world applicability.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eImmunotherapy has revolutionized cancer care, offering long-term benefits that were once thought impossible for many cancer patients. These treatments work by harnessing the body's own immune system to identify and destroy cancer cells while sparing healthy tissue—something traditional treatments like chemotherapy and radiation cannot do.\u003c\/p\u003e\n\n\u003cp\u003eHowever, immunotherapy has faced significant setbacks when applied to complex solid tumors like glioblastoma (GBM), the most common and aggressive form of brain cancer. GBM is notably difficult to treat because it creates a highly immunosuppressive environment, essentially \"turning off\" the very immune cells that immunotherapy is trying to activate.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers point out a critical disconnect: despite multiple immunotherapy approaches showing promise in early-phase trials, they have repeatedly failed to demonstrate meaningful benefit in large randomized controlled trials. This pattern has resulted in tens of millions of dollars invested without therapeutic gain for patients.\u003c\/p\u003e\n\n\u003cp\u003ePerhaps most importantly, GBM is fundamentally a disease of older adults, with a median age at diagnosis of 64 years. Yet very little research has examined how the aging immune system—which naturally weakens over time—affects a patient's ability to respond to immunotherapy. This study was designed to address that gap.\u003c\/p\u003e\n\n\u003ch2 id=\"aging-immune\"\u003eThe Aging Immune System Explained\u003c\/h2\u003e\n\n\u003cp\u003eThe human immune system begins to decline around age 50, with significant thymic atrophy (shrinking of the thymus gland, where immune cells mature) taking hold by age 65. This leads to major shifts in the balance of circulating T-cells, the specialized white blood cells that coordinate the immune response.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIncreased senescent T-cells:\u003c\/strong\u003e These are \"retired\" immune cells that no longer divide or function properly but accumulate with age.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLoss of effector memory cells:\u003c\/strong\u003e These are the cells that \"remember\" past infections and respond quickly to re-exposure, and their decline weakens vaccine responses.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeakened vaccine response:\u003c\/strong\u003e The immune system's ability to generate protective immunity from vaccines declines with age—this is why the CDC recommends vaccine boosters for individuals over age 65 for flu, COVID-19, and shingles.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe researchers raise a critical question: if we know the aging immune system responds poorly to vaccines for infectious diseases, why wouldn't it also respond poorly to cancer vaccines and other immunotherapies designed to train the immune system? This study aimed to answer that question using real patient data from clinical trials.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eStudy Methods: How the Research Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThe research team performed a systematic review and meta-analysis following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines—the gold standard for this type of research. They searched the PubMed and Cochrane databases for registered clinical trials conducted from January 1, 2000, through April 1, 2025.\u003c\/p\u003e\n\n\u003cp\u003eThe search included a comprehensive list of terms related to glioblastoma immunotherapy, including:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\"Glioblastoma and immunotherapy\"\u003c\/li\u003e\n  \u003cli\u003e\"Glioblastoma and virus\"\u003c\/li\u003e\n  \u003cli\u003e\"Glioblastoma and cellular vaccination\"\u003c\/li\u003e\n  \u003cli\u003e\"Glioblastoma and peptide vaccination\"\u003c\/li\u003e\n  \u003cli\u003e\"Glioblastoma and checkpoint inhibitors\" (medications like PD-1 and CTLA-4 inhibitors)\u003c\/li\u003e\n  \u003cli\u003e\"Glioblastoma and PD-1\"\u003c\/li\u003e\n  \u003cli\u003e\"Glioblastoma and CTLA-4\"\u003c\/li\u003e\n  \u003cli\u003e\"Glioblastoma and cytokine therapy\"\u003c\/li\u003e\n  \u003cli\u003e\"Glioblastoma and CAR-T\" (engineered immune cells)\u003c\/li\u003e\n  \u003cli\u003e\"Glioblastoma and immune stimulation\"\u003c\/li\u003e\n  \u003cli\u003e\"Glioblastoma and immune microenvironment\"\u003c\/li\u003e\n  \u003cli\u003e\"Glioblastoma and dendritic cell vaccination\"\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eInclusion criteria and age grouping:\u003c\/strong\u003e Only phase II, III, and IV clinical trials were included. Each trial's participants were grouped into two categories: aged (65 years and older, considered the \"experimental\" group) and young (64 and under, considered the \"control\" group). The primary outcome was overall survival (OS) at one year post-treatment.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eStatistical analysis:\u003c\/strong\u003e The pooled risk ratio (RR) of death at or before one year was calculated using both random and common effects models, with the random effects model calculated by the Mantel-Haenszel method. Heterogeneity (variability between studies) was assessed using the I² statistic, and publication bias was evaluated using contoured funnel plots. Analyses were conducted using R Version 4.4.2 with the meta package version 8.2-1. Data extraction was performed by three independent investigators and verified by a final review.\u003c\/p\u003e\n\n\u003cp\u003eIn total, \u003cstrong\u003e30 studies met the inclusion criteria, encompassing 556 patients\u003c\/strong\u003e—98 patients aged 65 or older and 458 patients aged 64 or younger. A full list of the included phase II trials is shown in the table below.\u003c\/p\u003e\n\n\u003ctable border=\"1\" cellpadding=\"6\" cellspacing=\"0\"\u003e\n  \u003ccaption\u003e\u003cstrong\u003ePhase II GBM Immunotherapy Trials Included in the Meta-Analysis\u003c\/strong\u003e\u003c\/caption\u003e\n  \u003ctr\u003e\n    \u003cth\u003eStudy Author (Year)\u003c\/th\u003e\n    \u003cth\u003eImmunotherapy Type\u003c\/th\u003e\n    \u003cth\u003ePrimary or Recurrent\u003c\/th\u003e\n    \u003cth\u003e% Aged (65+) in Trial\u003c\/th\u003e\n    \u003cth\u003eTotal N\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eInoges 2017\u003c\/td\u003e\n\u003ctd\u003eDC Vax whole lysate\u003c\/td\u003e\n\u003ctd\u003ePrimary\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003ctd\u003e31\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eWeathers 2020\u003c\/td\u003e\n\u003ctd\u003eCMV specific expanded T-cells\u003c\/td\u003e\n\u003ctd\u003eMixed\u003c\/td\u003e\n\u003ctd\u003e5%\u003c\/td\u003e\n\u003ctd\u003e20\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eCho 2012\u003c\/td\u003e\n\u003ctd\u003eDC Vax whole lysate\u003c\/td\u003e\n\u003ctd\u003ePrimary\u003c\/td\u003e\n\u003ctd\u003e6%\u003c\/td\u003e\n\u003ctd\u003e18\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eBatich 2020\u003c\/td\u003e\n\u003ctd\u003eCMV targeted DC vax\u003c\/td\u003e\n\u003ctd\u003ePrimary\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003ctd\u003e23\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eLim 2021\u003c\/td\u003e\n\u003ctd\u003eEx-vivo expanded\/activated T and NK cells\u003c\/td\u003e\n\u003ctd\u003eRecurrent\u003c\/td\u003e\n\u003ctd\u003e7%\u003c\/td\u003e\n\u003ctd\u003e14\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eIzumoto 2008\u003c\/td\u003e\n\u003ctd\u003ePeptide vaccine for WT1 antigen\u003c\/td\u003e\n\u003ctd\u003eRecurrent\u003c\/td\u003e\n\u003ctd\u003e19%\u003c\/td\u003e\n\u003ctd\u003e21\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eGeletneky 2017\u003c\/td\u003e\n\u003ctd\u003eOncolytic parvovirus\u003c\/td\u003e\n\u003ctd\u003eRecurrent\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003ctd\u003e18\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eWheeler 2008\u003c\/td\u003e\n\u003ctd\u003eDC Vax whole lysate\u003c\/td\u003e\n\u003ctd\u003eMixed\u003c\/td\u003e\n\u003ctd\u003e15%\u003c\/td\u003e\n\u003ctd\u003e34\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eTamura 2020\u003c\/td\u003e\n\u003ctd\u003ePeptide vaccine to VEGF\u003c\/td\u003e\n\u003ctd\u003ePrimary\u003c\/td\u003e\n\u003ctd\u003e25%\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eFadul 2011\u003c\/td\u003e\n\u003ctd\u003eDC Vax whole lysate\u003c\/td\u003e\n\u003ctd\u003ePrimary\u003c\/td\u003e\n\u003ctd\u003e40%\u003c\/td\u003e\n\u003ctd\u003e10\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eMigliorini 2019\u003c\/td\u003e\n\u003ctd\u003eMulti-peptide vaccine\u003c\/td\u003e\n\u003ctd\u003ePrimary\u003c\/td\u003e\n\u003ctd\u003e31%\u003c\/td\u003e\n\u003ctd\u003e16\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eYamanaka 2003\u003c\/td\u003e\n\u003ctd\u003eDC Vax whole lysate\u003c\/td\u003e\n\u003ctd\u003eRecurrent\u003c\/td\u003e\n\u003ctd\u003e29%\u003c\/td\u003e\n\u003ctd\u003e7\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eChang 2011\u003c\/td\u003e\n\u003ctd\u003eDC Vax autologous\u003c\/td\u003e\n\u003ctd\u003eMixed\u003c\/td\u003e\n\u003ctd\u003e14%\u003c\/td\u003e\n\u003ctd\u003e14\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eTodo 2022\u003c\/td\u003e\n\u003ctd\u003eOncolytic herpes virus\u003c\/td\u003e\n\u003ctd\u003eRecurrent\u003c\/td\u003e\n\u003ctd\u003e21%\u003c\/td\u003e\n\u003ctd\u003e19\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eTodo 2022\u003c\/td\u003e\n\u003ctd\u003eOncolytic herpes virus\u003c\/td\u003e\n\u003ctd\u003eRecurrent\u003c\/td\u003e\n\u003ctd\u003e8%\u003c\/td\u003e\n\u003ctd\u003e13\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eSchalper 2019\u003c\/td\u003e\n\u003ctd\u003eNeoadjuvant nivolumab\u003c\/td\u003e\n\u003ctd\u003eMixed\u003c\/td\u003e\n\u003ctd\u003e17%\u003c\/td\u003e\n\u003ctd\u003e30\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eVik-MO 2013\u003c\/td\u003e\n\u003ctd\u003eDC Vax targeted to stem cells\u003c\/td\u003e\n\u003ctd\u003ePrimary\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003ctd\u003e7\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eJan 2018\u003c\/td\u003e\n\u003ctd\u003eDC Vax autologous\u003c\/td\u003e\n\u003ctd\u003ePrimary\u003c\/td\u003e\n\u003ctd\u003e7%\u003c\/td\u003e\n\u003ctd\u003e27\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eHunn 2014\u003c\/td\u003e\n\u003ctd\u003eDC Vax autologous\u003c\/td\u003e\n\u003ctd\u003eRecurrent\u003c\/td\u003e\n\u003ctd\u003e14%\u003c\/td\u003e\n\u003ctd\u003e14\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eRudnick 2020\u003c\/td\u003e\n\u003ctd\u003eDC Vax + Glidel wafer\u003c\/td\u003e\n\u003ctd\u003eMixed\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003ctd\u003e23\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eDesjardins 2018\u003c\/td\u003e\n\u003ctd\u003ePoliovirus\u003c\/td\u003e\n\u003ctd\u003eRecurrent\u003c\/td\u003e\n\u003ctd\u003e13%\u003c\/td\u003e\n\u003ctd\u003e61\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eHilf 2018\u003c\/td\u003e\n\u003ctd\u003eNeoantigen peptide vaccine\u003c\/td\u003e\n\u003ctd\u003ePrimary\u003c\/td\u003e\n\u003ctd\u003e19%\u003c\/td\u003e\n\u003ctd\u003e16\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eChiocca 2011\u003c\/td\u003e\n\u003ctd\u003eOncolytic herpes virus\u003c\/td\u003e\n\u003ctd\u003ePrimary\u003c\/td\u003e\n\u003ctd\u003e20%\u003c\/td\u003e\n\u003ctd\u003e10\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003ePrins 2011\u003c\/td\u003e\n\u003ctd\u003eDC Vax\u003c\/td\u003e\n\u003ctd\u003eMixed\u003c\/td\u003e\n\u003ctd\u003e13%\u003c\/td\u003e\n\u003ctd\u003e23\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003evan Putten 2022\u003c\/td\u003e\n\u003ctd\u003eConvection-enhanced delivery of oncolytic virus\u003c\/td\u003e\n\u003ctd\u003eRecurrent\u003c\/td\u003e\n\u003ctd\u003e16%\u003c\/td\u003e\n\u003ctd\u003e19\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eFreeman 2006\u003c\/td\u003e\n\u003ctd\u003eOncolytic virus\u003c\/td\u003e\n\u003ctd\u003eRecurrent\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003ctd\u003e11\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eLiau 2005\u003c\/td\u003e\n\u003ctd\u003eDC vaccine\u003c\/td\u003e\n\u003ctd\u003eMixed\u003c\/td\u003e\n\u003ctd\u003e8%\u003c\/td\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eBrown 2022\u003c\/td\u003e\n\u003ctd\u003eCAR-T with steroid resistance\u003c\/td\u003e\n\u003ctd\u003eRecurrent\u003c\/td\u003e\n\u003ctd\u003e17%\u003c\/td\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eSmith 2020\u003c\/td\u003e\n\u003ctd\u003eCMV specific expanded T-cells\u003c\/td\u003e\n\u003ctd\u003ePrimary\u003c\/td\u003e\n\u003ctd\u003e14%\u003c\/td\u003e\n\u003ctd\u003e21\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eMitsuya 2020\u003c\/td\u003e\n\u003ctd\u003eDC Vax synthetic cocktail pulse\u003c\/td\u003e\n\u003ctd\u003ePrimary\u003c\/td\u003e\n\u003ctd\u003e36%\u003c\/td\u003e\n\u003ctd\u003e14\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch2 id=\"findings-overall\"\u003eKey Finding #1: Higher Risk of Death in Older Patients\u003c\/h2\u003e\n\n\u003cp\u003eThe most important finding was that \u003cstrong\u003epatients aged 65 and older had a significantly higher risk of death at or before one year after immunotherapy treatment\u003c\/strong\u003e compared to younger patients. The pooled risk ratio across all 30 studies was \u003cstrong\u003e1.29 (95% confidence interval: 1.09–1.53, p = 0.004)\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eIn plain language: older patients had a 29% higher risk of dying within one year of treatment compared to patients under 65. This result was statistically significant (p = 0.004), meaning there is less than a 0.4% chance this finding was due to random chance alone.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers also checked for publication bias—the tendency for studies with positive results to be published more often than those with negative results. The I² statistic was only 10.9%, indicating very little heterogeneity (variability) between the studies and lending confidence to the pooled result.\u003c\/p\u003e\n\n\u003cp\u003eTo further strengthen their analysis, the team performed a single-patient-level analysis examining known predictors of survival in GBM: MGMT methylation status, IDH mutation status, and gender. Of the 213 patients with newly diagnosed GBM in the included studies, only 96 had complete data on all these factors. ANOVA analysis demonstrated \u003cstrong\u003eno significant predictive value for any of these variables on overall survival\u003c\/strong\u003e, suggesting that age itself—not these other factors—was driving the observed differences in outcomes.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers also looked at published phase III clinical trials that had calculated hazard ratios (a measure of risk over time) for age. They identified only 4 trials that had conducted this type of analysis, and while the data showed no significant effect of age on immunotherapy outcomes in these larger trials, all of these trials included disproportionately few patients over age 65—hampering any meaningful conclusions.\u003c\/p\u003e\n\n\u003ch2 id=\"findings-newly\"\u003eKey Finding #2: Age Matters More in Newly Diagnosed GBM\u003c\/h2\u003e\n\n\u003cp\u003eResearchers hypothesized that immunotherapy would be more beneficial when given at the time of initial diagnosis rather than waiting until the tumor recurs. They separated the trial data into newly diagnosed GBM and recurrent GBM to see how age affected outcomes in each group.\u003c\/p\u003e\n\n\u003cp\u003eThe results were striking:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNewly diagnosed GBM:\u003c\/strong\u003e The risk ratio of death at or before 1 year for aged patients was \u003cstrong\u003e2.34 (95% CI: 1.39–3.61, p = 0.0026)\u003c\/strong\u003e—meaning older patients had more than double the risk of dying within one year compared to younger patients.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRecurrent GBM:\u003c\/strong\u003e The risk ratio was lower but still significant at \u003cstrong\u003e1.23 (95% CI: 1.05–1.42, p = 0.0119)\u003c\/strong\u003e—a 23% increased risk for older patients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eBoth analyses had I² statistics below 10%, indicating very low heterogeneity and strong reliability of the findings. When the researchers compared the risk ratios and confidence intervals between the two groups, there was little overlap, confirming that the age effect was genuinely larger in newly diagnosed disease.\u003c\/p\u003e\n\n\u003cp\u003eThis finding is particularly important because many experts believe immunotherapy has the best chance of working when the tumor is first diagnosed, before it has fully established its immunosuppressive defenses. If older patients are not benefiting as much at this critical early timepoint, it suggests the aging immune system may be unable to mount the robust response that immunotherapy requires.\u003c\/p\u003e\n\n\u003ch2 id=\"findings-vaccine\"\u003eKey Finding #3: Vaccine-Based Therapies May Be More Affected by Age\u003c\/h2\u003e\n\n\u003cp\u003eOne well-documented effect of immune system aging is the reduced response to vaccinations. This has been extensively studied for infections like flu, COVID-19, and shingles, but rarely examined in the context of cancer vaccines.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers divided the trials into two categories:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eVaccine-based immunotherapies:\u003c\/strong\u003e Including dendritic cell (DC) vaccines and peptide vaccines, which work by training the immune system to recognize and attack tumor cells.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNon-vaccine-based immunotherapies:\u003c\/strong\u003e Including checkpoint inhibitors, oncolytic viruses, CAR-T cells, and other approaches.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFor \u003cstrong\u003evaccine-based immunotherapies\u003c\/strong\u003e, older patients had a significantly higher risk of death at or before 1 year: \u003cstrong\u003erisk ratio 1.38 (95% CI: 1.04–1.83, p = 0.0294)\u003c\/strong\u003e—a 38% increased risk.\u003c\/p\u003e\n\n\u003cp\u003eFor \u003cstrong\u003enon-vaccine-based immunotherapies\u003c\/strong\u003e, the increased risk was smaller and not statistically significant: \u003cstrong\u003erisk ratio 1.23 (95% CI: 0.95–1.58, p = 0.1032)\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eWhen the confidence intervals of the two groups were compared, they overlapped significantly, indicating the difference between vaccine and non-vaccine therapies may be weak or nonexistent with current data. The smaller sample size in the non-vaccine group did increase the I² statistic, but it remained under 30%, indicating low to no publication bias or heterogeneity.\u003c\/p\u003e\n\n\u003cp\u003eThis finding suggests that the age-related decline in vaccine response—so well documented for infectious diseases—may also apply to cancer vaccines. However, the researchers emphasize that more targeted studies are needed to fully explore this possibility.\u003c\/p\u003e\n\n\u003ch2 id=\"findings-bias\"\u003eKey Finding #4: Clinical Trials Are Skewed Toward Younger Patients\u003c\/h2\u003e\n\n\u003cp\u003eDuring the literature review, the researchers noticed a troubling pattern: GBM clinical trials were enrolling younger patients than the actual GBM patient population. This matters because if trial results don't reflect the real patient population, the findings may not apply to the people who most need the treatment.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePhase II trials:\u003c\/strong\u003e Across the 30 studies and 556 patients, only \u003cstrong\u003e18% of participants were aged 65 or older\u003c\/strong\u003e. When calculated as proportions across studies, there was a highly significant difference: \u003cstrong\u003e17% aged vs. 82% younger patients (p \u0026lt; 0.0001)\u003c\/strong\u003e. Notably, no study included more than 40% aged individuals.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePhase III trials:\u003c\/strong\u003e The researchers examined 9 phase III GBM immunotherapy trials with 2,342 patients and found similar bias: only \u003cstrong\u003e26% of enrolled participants were over age 65\u003c\/strong\u003e (26% vs. 73%, p \u0026lt; 0.0001).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eComparison to lung cancer:\u003c\/strong\u003e To determine whether this was a pervasive problem across oncology, the researchers applied the same analysis to lung cancer immunotherapy trials—another cancer diagnosed in older adults, with a median age at diagnosis of about 70 years. Remarkably, lung cancer trials showed nearly a \u003cstrong\u003e50\/50 split\u003c\/strong\u003e between patients above and below age 65, with no statistically significant difference in the proportion of older patients (more than 50% of lung cancer phase III trial participants were over 65).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDirect comparison:\u003c\/strong\u003e The average age of participants in phase III GBM immunotherapy trials was \u003cstrong\u003e57 years\u003c\/strong\u003e, compared to \u003cstrong\u003e67 years\u003c\/strong\u003e in lung cancer trials—a difference that was highly statistically significant (p \u0026lt; 0.0001).\u003c\/p\u003e\n\n\u003cp\u003eThe table below summarizes the phase III GBM trials examined for age bias:\u003c\/p\u003e\n\n\u003ctable border=\"1\" cellpadding=\"6\" cellspacing=\"0\"\u003e\n  \u003ccaption\u003e\u003cstrong\u003ePhase III GBM Immunotherapy Trials Examined for Age Bias\u003c\/strong\u003e\u003c\/caption\u003e\n  \u003ctr\u003e\n    \u003cth\u003eStudy Author (Year)\u003c\/th\u003e\n    \u003cth\u003e% Aged Patients\u003c\/th\u003e\n    \u003cth\u003eMean\/Median Age\u003c\/th\u003e\n    \u003cth\u003eTotal N\u003c\/th\u003e\n    \u003cth\u003eAge Subgroup Analysis?\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eReardon 2020\u003c\/td\u003e\n\u003ctd\u003e23%\u003c\/td\u003e\n\u003ctd\u003e55\u003c\/td\u003e\n\u003ctd\u003e184\u003c\/td\u003e\n\u003ctd\u003eNo\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eReardon 2020\u003c\/td\u003e\n\u003ctd\u003e16%\u003c\/td\u003e\n\u003ctd\u003e55\u003c\/td\u003e\n\u003ctd\u003e185\u003c\/td\u003e\n\u003ctd\u003eNo\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eLassman 2025\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e59.5\u003c\/td\u003e\n\u003ctd\u003e80\u003c\/td\u003e\n\u003ctd\u003eNo\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eLassman 2025\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e61\u003c\/td\u003e\n\u003ctd\u003e79\u003c\/td\u003e\n\u003ctd\u003eNo\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eKong 2016\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e53\u003c\/td\u003e\n\u003ctd\u003e91\u003c\/td\u003e\n\u003ctd\u003eNo\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eKong 2016\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e53\u003c\/td\u003e\n\u003ctd\u003e89\u003c\/td\u003e\n\u003ctd\u003eNo\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eNarita 2018\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e52.5\u003c\/td\u003e\n\u003ctd\u003e58\u003c\/td\u003e\n\u003ctd\u003eYes—found age \u0026lt;70 was an HR increase, but \u0026lt;50 or 50–69 wasn't significantly different\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eNarita 2018\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e59\u003c\/td\u003e\n\u003ctd\u003e30\u003c\/td\u003e\n\u003ctd\u003e(same trial arms)\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eLiau 2023\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e232\u003c\/td\u003e\n\u003ctd\u003eYes—found both ages \u0026gt; and \u0026lt; 65 favored DC vax\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eLiau 2023\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e56\u003c\/td\u003e\n\u003ctd\u003e64\u003c\/td\u003e\n\u003ctd\u003e(same trial arms)\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eWestphal 2015\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e53\u003c\/td\u003e\n\u003ctd\u003e71\u003c\/td\u003e\n\u003ctd\u003eNo\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eWestphal 2015\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e56\u003c\/td\u003e\n\u003ctd\u003e71\u003c\/td\u003e\n\u003ctd\u003eNo\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eLim 2022\u003c\/td\u003e\n\u003ctd\u003e32%\u003c\/td\u003e\n\u003ctd\u003e60\u003c\/td\u003e\n\u003ctd\u003e358\u003c\/td\u003e\n\u003ctd\u003eYes—found age does worse in immunotherapy but only over 75; 65–75 wasn't significant\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eLim 2022\u003c\/td\u003e\n\u003ctd\u003e34%\u003c\/td\u003e\n\u003ctd\u003e60\u003c\/td\u003e\n\u003ctd\u003e358\u003c\/td\u003e\n\u003ctd\u003e(same trial arms)\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eWeller 2017 (partial data available)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis study provides some of the first comprehensive evidence that \u003cstrong\u003epatient age may significantly impact the effectiveness of immunotherapy for glioblastoma\u003c\/strong\u003e. For older patients considering immunotherapy, this research highlights several important points:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAge matters most at diagnosis:\u003c\/strong\u003e The effect of age was strongest in newly diagnosed GBM, where older patients had more than double the risk of death within one year. This is especially relevant since GBM is most commonly diagnosed in people in their 60s and 70s.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eVaccine-based therapies may be particularly affected:\u003c\/strong\u003e If you're considering a dendritic cell vaccine or peptide vaccine, understand that the aging immune system may not respond as robustly as a younger person's immune system would.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTrial results may not apply to you:\u003c\/strong\u003e Since GBM clinical trials have historically enrolled far fewer older patients, the published results of these trials may overestimate the benefits of immunotherapy in the real-world older GBM population.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe researchers emphasize that these findings should not necessarily discourage older patients from pursuing immunotherapy—rather, they highlight the need for more honest conversations between patients, families, and doctors about expected outcomes. They also underscore the need for clinical trials specifically designed to evaluate immunotherapy in older adults, rather than extrapolating from younger patient data.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations: What This Research Couldn't Prove\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers were transparent about the limitations of their analysis:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHigh risk of bias in all included trials:\u003c\/strong\u003e Using the Cochrane risk-of-bias tool, all 30 trials scored in the \"high risk\" category, primarily due to the lack of true randomization in their designs. This is a common limitation in phase II cancer trials.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIncomplete individual patient data:\u003c\/strong\u003e Of 213 patients with newly diagnosed GBM, only 96 had complete data on all predictive factors (MGMT methylation, IDH mutation, and gender), limiting the power of the subgroup analysis.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFew phase III trials reported age breakdowns:\u003c\/strong\u003e Only 4 phase III trials had calculated hazard ratios for age, and all included very few patients over 65, limiting meaningful conclusions from these larger studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eReview was not pre-registered:\u003c\/strong\u003e The authors noted that this review was not pre-registered and a pre-protocol was not prepared, which some researchers view as a methodological limitation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSmall subgroup sample sizes:\u003c\/strong\u003e The non-vaccine-based immunotherapy cohort had a smaller sample size, which increased the I² statistic (though it remained below 30%, indicating acceptable levels of heterogeneity).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eObservational nature:\u003c\/strong\u003e This is a meta-analysis of existing trial data, not a prospective study. It can identify associations but cannot prove that aging directly causes poorer immunotherapy outcomes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients and Researchers\u003c\/h2\u003e\n\n\u003cp\u003eBased on their findings, the researchers make several specific recommendations:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFor researchers:\u003c\/strong\u003e Track and report age-specific outcomes in all immunotherapy trials. The authors noted that \"trial designs with better tracking and reporting of this variable will allow for a more careful examination of this effect and overall successful immunotherapy development.\"\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFor trial sponsors:\u003c\/strong\u003e Actively recruit older patients into GBM immunotherapy trials to ensure the trial population reflects the actual disease population. The current bias toward younger patients—not seen in lung cancer trials—must be corrected.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFor older GBM patients:\u003c\/strong\u003e Ask your doctor about whether the clinical trial evidence for any proposed immunotherapy includes patients in your age group. If older patients were underrepresented in the trials, ask what that might mean for your expected outcomes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFor the research community:\u003c\/strong\u003e Recognize that the aging immune system—with its decline in T-cell function, thymic atrophy, and weakened vaccine response—may be a fundamental biological factor in immunotherapy efficacy. This should be studied as a primary variable, not an afterthought.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFor future studies:\u003c\/strong\u003e Conduct more targeted research on vaccine-based immunotherapies in older adults, given the well-documented age-related decline in vaccine response that was reflected in this analysis.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe broader message is clear: as the U.S. population ages rapidly, and since cancer—including GBM—is fundamentally a disease of older adults, understanding how immunotherapy interacts with the aging immune system is not optional. It is essential for ensuring that the promise of immunotherapy extends to all patients who need it, regardless of age.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhy might older adults respond worse to glioblastoma immunotherapy?\u003c\/h3\u003e\n\u003cp\u003eThe immune system weakens with age, especially after 65. Older adults have more senescent T-cells, fewer memory cells, and a weaker response to vaccines. Since many immunotherapies train the immune system, this age-related decline may reduce their effectiveness in older glioblastoma patients.\u003c\/p\u003e\n\u003ch3\u003eAre vaccine-based immunotherapies more affected by age than other types?\u003c\/h3\u003e\n\u003cp\u003ePossibly. For vaccine therapies like dendritic cell or peptide vaccines, older patients had a 38% higher risk of death within one year. For non-vaccine therapies, the increase was smaller and not statistically significant. However, the difference between the two may be weak.\u003c\/p\u003e\n\u003ch3\u003eAre glioblastoma clinical trials representative of older patients?\u003c\/h3\u003e\n\u003cp\u003eNo. Only 18% of participants in phase II GBM immunotherapy trials were 65 or older, and 26% in phase III trials. This is far lower than the real-world GBM population, where median age at diagnosis is 64. Results may not apply to older patients.\u003c\/p\u003e\n\u003ch3\u003eShould older patients with glioblastoma avoid immunotherapy because of this study?\u003c\/h3\u003e\n\u003cp\u003eNot necessarily. The researchers say these findings should not discourage older patients from pursuing immunotherapy. Instead, they emphasize honest conversations with doctors about expected outcomes and the need for trials that include older adults. Your doctor can help weigh risks and benefits.\u003c\/p\u003e\n\u003ch3\u003eWhat should I ask my doctor before starting immunotherapy for glioblastoma?\u003c\/h3\u003e\n\u003cp\u003eAsk whether the clinical trial evidence for the proposed immunotherapy included patients in your age group. If older patients were underrepresented, ask what that might mean for your expected outcomes. Also ask if your age could affect how well the treatment works, especially if it is a vaccine-based therapy.\u003c\/p\u003e\n\u003ch3\u003eIf I'm over 65 with glioblastoma, should I get a second opinion about immunotherapy?\u003c\/h3\u003e\n\u003cp\u003ePatients aged 65 and older with glioblastoma had a 29% higher risk of death within one year of immunotherapy than younger patients, and more than double the risk among newly diagnosed cases. Clinical trials for glioblastoma immunotherapy have enrolled very few older adults, so published results may not reflect your expected outcome. A second opinion can help you ask whether the proposed immunotherapy has evidence for patients in your age group, especially for vaccine-based therapies, which appeared more affected by age. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Glioblastoma immunotherapy in the context of the aging immune system: a systematic review and meta-analysis.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Shireman JM, Ammanuel S, Cheng L, Distler E, Tao Y, Kendziorski C, Dey M.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Journal of Neuro-Oncology (2026), Volume 176, Article 164\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e https:\/\/doi.org\/10.1007\/s11060-025-05395-1\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublished online:\u003c\/strong\u003e January 12, 2026 (received November 8, 2025; accepted December 18, 2025)\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAffiliations:\u003c\/strong\u003e Department of Neurosurgery, University of Wisconsin School of Medicine \u0026amp; Public Health, UW Carbone Cancer Center; and Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA\u003c\/p\u003e\n\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research. The original study was funded and conducted by researchers at the University of Wisconsin, and the full text is available through the Journal of Neuro-Oncology. This translation is provided for educational purposes and does not constitute medical advice. Patients should discuss their individual treatment options with their healthcare team.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47527659700380,"sku":null,"price":0.0,"currency_code":"KRW","in_stock":true}],"url":"https:\/\/diagnosticdetectives.kr\/products\/glioblastoma-immunotherapy-and-the-aging-immune-system-what-older-patients-need-to-know","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}